Mark J Enyedy
CIK 1586965 · CHIEF EXECUTIVE OFFICER · last filed 2026-06-04
Mark J Enyedy is a CHIEF EXECUTIVE OFFICER who has filed 43 SEC Form 4 insider transactions across 7 companies since 2015. The most recent filing, for BMRN, was dated Jun 4, 2026. Across all open-market trades the lifetime net is −$53.0M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $1.7M across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$1.65M
7
43
-$52.99M
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| BMRN | Director | 21,040 | $55.95 | $1.18M | $0 | 4 | 2026-06-04 |
| CRL | Director | 2,384 | $187.51 | $447.0K | $0 | 2 | 2026-05-11 |
| ImmunoGen, Inc. (IMGN) Delisted | CHIEF EXECUTIVE OFFICER | 0 | $31.23 | $0 | -$52.99M | 22 | 2024-02-12 |
| LOGC | Director | 0 | $7.06 | $0 | $0 | 6 | 2022-11-17 |
| AKBA | Director | 31,143 | $0.92 | $28.8K | $0 | 3 | 2020-06-09 |
| KERYX BIOPHARMACEUTICALS INC (KERX) Delisted | Director | 0 | — | — | $0 | 3 | 2018-12-13 |
| FATE | Director | — | $2.06 | — | $0 | 3 | 2017-05-04 |
Recent Filings
43 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-06-04 | BMRN | Grant (A) | +7,490 | $0 | EDGAR |
| 2026-05-11 | CRL | Grant (A) | +1,438 | $255.4K | EDGAR |
| 2025-06-04 | CRL | Grant (A) | +946 | $127.7K | EDGAR |
| 2025-05-22 | BMRN | Grant (A) | +6,650 | $0 | EDGAR |
| 2024-05-23 | BMRN | Grant (A) | +4,720 | $0 | EDGAR |
| 2024-02-12 | ImmunoGen, Inc. (IMGN) Delisted | Disp (D) | −584,397 | $0 | EDGAR |
| 2024-02-06 | ImmunoGen, Inc. (IMGN) Delisted | Mixed | +31,127 | -$588.7K | EDGAR |
| 2024-02-05 | ImmunoGen, Inc. (IMGN) Delisted | Grant (A) | — | $0 | EDGAR |
| 2023-12-28 | BMRN | Grant (A) | +2,180 | $0 | EDGAR |
| 2023-08-04 | ImmunoGen, Inc. (IMGN) Delisted | Mixed | +111,821 | -$36.07M | EDGAR |